Bernard Fischbach, MD
Nephrology · Fort Worth, TXNPI 1225016819
Payments from drug & device makers
Across 335 payments — averaging $2598.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$265K
- Eli Lilly$242K
- CSL Behring$128K
- Vertex$119K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$28K
- E.r. Squibb & Sons, L.L.C.$24K
- plus $64K from 26 others
Across 3 payments — averaging $40,821 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$122K
What the payments were for
- Travel & lodging$36813%
- Food & beverage$2,54287%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 35 | $265,409 |
| Eli Lilly | 21 | $242,393 |
| CSL Behring | 165 | $127,747 |
| Vertex | 3 | $118,707 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $28,045 |
| E.r. Squibb & Sons, L.L.C. | 3 | $24,460 |
| Biogen | 1 | $16,509 |
| Novartis | 4 | $14,587 |
| Shire North American Group Inc | 6 | $13,677 |
| Bayer | 4 | $10,285 |
| Travere Therapeutics, Inc. | 10 | $6,741 |
| Amgen(2 entities) | 24 | $547 |
| AstraZeneca(2 entities) | 12 | $207 |
| Veloxis Pharmaceuticals, Inc. | 6 | $163 |
| Mallinckrodt Hospital Products Inc. | 6 | $150 |
| One Lambda, Inc. | 1 | $129 |
| Aurinia Pharma U.S., Inc. | 5 | $123 |
| Fresenius USA Marketing, Inc. | 6 | $113 |
| Sanofi | 4 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Merck | 2 | $40 |
| OPKO Pharmaceuticals, LLC | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Amicus Therapeutics, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $12 |
| AbbVie | 1 | $12 |
How this compares
$870,395 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NulojixBelatacept | 33 | $68,024 |
| Cinacalcet Hcl | 108 | $31,316 |
| Valganciclovir Hcl | 158 | $24,660 |
| EliquisApixaban | 22 | $15,895 |
| Envarsus XrTacrolimus | 17 | $11,454 |
| Mycophenolic AcidMycophenolate Sodium | 40 | $10,237 |
| Atovaquone | 21 | $10,129 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $9,749 |
| FarxigaDapagliflozin Propanediol | 12 | $6,876 |
| Tacrolimus | 43 | $6,470 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 64 | $6,434 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $5,584 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 907 | $5,438 |
| Nifedipine ErNifedipine | 226 | $4,696 |
| Mycophenolate Mofetil | 50 | $4,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Nulojix | $24,460 | $68,02433 claims |
| AstraZenecaFarxiga | $207 | $6,87612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Fort Worth
- Saravanan BalamuthusamyFort Worth$707K
- Pablo PergolaSan Antonio$14.2M
- German HernandezEl Paso$9.7M
- Sreedhar MandayamHouston$7M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Marializa BernardoHouston$4.2M
- Judith BettsAustin$3.7M
- Wesley CalhounSan Antonio$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.